grant

Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells.

Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 1 Jan 2025Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY2025Amino Acid ChannelAmino Acid Transport SystemsAmino Acid TransporterAmino AcidsAntigensAssayAttenuatedAutomobile DrivingAutoregulationBioassayBiological AssayCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer PatientCancersCell BodyCell FunctionCell PhysiologyCell ProcessCell-Mediated Lympholytic CellsCellsCellular FunctionCellular PhysiologyCellular ProcessChronicClinicalCytokine SuppressionCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesDataDevelopment PlansDevelopment and ResearchDysfunctionElementsEnvironmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExhibitsFailureFibroblastsFunctional RNAFunctional disorderGene TranscriptionGenesGenetic TranscriptionGlnGlutamineGoalsHomeostasisImmuneImmune mediated therapyImmunesImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyImpairmentIndividualInfiltrationInflammatoryInterventionIntrinsic factorJointsL-GlutamineLytotoxicityMHC ReceptorMSKCCMajor Histocompatibility Complex ReceptorMalignant NeoplasmsMalignant TumorMediatingMemorial Sloan-Kettering Cancer CenterMentorshipMetabolicMicronutrientsNoncoding RNANontranslated RNANuclearNutrientPatientsPhysiological HomeostasisPhysiopathologyPlayPostdocPostdoctoral FellowProductionProtein BiosynthesisProteinsProteomeQ LevoglutamideQ. LevoglutamideR & DR&DR-Series Research ProjectsR01 MechanismR01 ProgramRNA ExpressionReceptor SignalingResearchResearch AssociateResearch GrantsResearch Project GrantsResearch ProjectsResearch ResourcesResistanceResourcesRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisRibosomal RNARibosomesRoleSmall RNASubcellular ProcessT cell based immune therapyT cell based therapeuticsT cell based therapyT cell differentiationT cell directed therapiesT cell immune therapyT cell immunotherapyT cell responseT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell Antigen ReceptorsT-Cell ReceptorT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT8 CellsT8 LymphocytesTeff cellTrainingTranscriptTranscriptionTransfer RNATranslationsTriplet Codon-Amino Acid AdaptorTumor ImmunityTumor SubtypeUntranslated RNAUpregulationWorkadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyamino acid metabolismaminoacidanti-cancer researchanti-tumor immunityantigen-specific T cellsantitumor immunityattenuateattenuatescancer immunitycancer infiltrating T cellscancer microenvironmentcancer researchcareer developmentcheck point blockadecheckpoint blockadechimeric antigen receptorcytokinecytotoxiccytotoxicitydeprivationdrivingeffector T cellepigeneticallyexhaustexhaustionexperienceextracellulargene signaturesgenetic signaturegraduate schoolimmune check pointimmune check point blockadeimmune checkpointimmune checkpoint blockadeimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunogenimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedin vivoinsightkiller T cellmRNA Translationmalignancyneoplasm/cancernew approachesnoncodingnotchnotch proteinnotch receptorsnovelnovel approachesnovel strategiesnovel strategyoverexpressoverexpressionpathophysiologypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespost-docpost-doctoralpost-doctoral traineeposttranscriptionalpre-docpre-doctoralproliferation capabilityproliferation capacityproliferation potentialproliferative capabilityproliferative capacityproliferative potentialprotein synthesisrRNAresearch and developmentresearch associatesresistantresponsesocial rolesuccesstRNAtherapeutic T-cell platformthymus derived lymphocytetranscriptomicstransfer Ribonucleic acidstranslationtumortumor infiltrating T cellstumor microenvironment
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY/ ABSTRACT
Immune checkpoint blockade (ICB), aimed at reinvigorating immune cells such as T-cells, has exhibited clinical

success in a subset of patients yet fails to be applicable to many tumor subtypes. These unresponsive subtypes

upregulate gene signatures associated with amino acid (AA) metabolism and deprivation. However, how AA

deprivation contribute to poor ICB response remains unclear. Upon chronic antigen stimulation, T-cells become

“exhausted”, an alternative differentiation state that entails the loss of cytotoxic effector function and proliferative

capacity. T-cell exhaustion involves extensive transcriptomic and epigenetic remodeling; however, the loss of

cytokine production occurs despite adequate expression of transcripts encoding cytokines, suggesting post-

transcriptional mechanisms of restricting effector function within tumors. The long-term goal is to elucidate the

mechanisms underlying T-cell dysfunction within the tumor microenvironment and leverage these insights to

enhance ICB efficacy. The predoctoral research (Aim 1) will aim to investigate how local AA availability limits

effector function in tumor-infiltrating T-cells. Preliminary data showed that intratumoral T-cells can not engage in

efficient translation and they experience glutamine deprivation in the tumor microenvironment. Elevated

translational demand downstream of chronic T-cell receptor signaling cannot be met when extracellular AAs are

limiting, restricting both global translation rate and cytotoxic cytokine production. Specific Aim 1.1 will seek to

determine how local AA availability impacts the exhausted T-cell proteome. Nascent transcriptomic and

translatomic alterations will be profiled to evaluate the impact of AA limitation on gene-specific translation rates,

followed by ribosomal footprinting assays to identify cell state- and AA-dependent stalling in vivo. Specific Aim

1.2 will investigate the impact of enhancing AA availability on ICB. A broad-spectrum AA transporter will be

overexpressed in T-cells to examine whether it enhances tumor control in response to ICB and overcomes the

immunosuppressive effects conferred by cancer-associated fibroblasts via restricting intratumoral AA availability.

My postdoctoral research (Aim 2) will focus on the role of non-coding RNAs in translational suppression during

terminal T-cell exhaustion. I will profile how T-cell exhaustion impact the expression of non-coding RNAs and

examine whether non-coding RNA subsequently modulates translation and cytokine production. Overall, these

two projects will unveil the distinct mechanisms driving T-cell dysfunction through translational suppression

during early tumor-infiltration and late terminal exhaustion. The research and training plan outlined in this

proposal will be completed with the joint mentorship of Dr. Santosha Vardhana and Dr. Jayanta Chaudhuri at

Memorial Sloan Kettering Cancer Center (MSK). MSK’s top-notch cancer research environment and abundant

resources in conjunction with the support of the Gerstner Sloan Kettering Graduate School will guarantee the

successful completion of the proposed research and career development plans.

Grant Number: 3F99CA294267-01S1
NIH Institute/Center: NIH

Principal Investigator: Yan-Ting Chen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →